{"id":"4-diaminopyridine","safety":{"commonSideEffects":[{"rate":null,"effect":"Paresthesia"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Seizures"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"3,4-diaminopyridine acts as a potassium channel blocker that enhances neuromuscular transmission by prolonging the duration of the action potential at presynaptic nerve terminals. This leads to increased calcium influx and greater acetylcholine release into the synaptic cleft. The drug is used to treat disorders of neuromuscular transmission where acetylcholine release is impaired.","oneSentence":"3,4-diaminopyridine blocks potassium channels on nerve terminals, prolonging action potentials and increasing acetylcholine release at the neuromuscular junction.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:57:24.671Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Lambert-Eaton myasthenic syndrome (LEMS)"},{"name":"Myasthenia gravis"}]},"trialDetails":[{"nctId":"NCT01441557","phase":"PHASE2, PHASE3","title":"Pilot Study on the Usefulness of 3,4-diaminopyridine in the Treatment of Botulism","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2011-09","conditions":"Botulism","enrollment":3},{"nctId":"NCT02189720","phase":"","title":"Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome","status":"APPROVED_FOR_MARKETING","sponsor":"Catalyst Pharmaceuticals, Inc.","startDate":"","conditions":"Congenital Myasthenic Syndrome, Lambert-Eaton Myasthenic Syndrome, Nystagmus, Acquired","enrollment":""},{"nctId":"NCT01765140","phase":"","title":"Treatment Use of 3,4-Diaminopyridine","status":"NO_LONGER_AVAILABLE","sponsor":"Vern C. Juel, M.D.","startDate":"","conditions":"Myasthenic Syndromes, Congenital","enrollment":""},{"nctId":"NCT03579966","phase":"PHASE3","title":"Long Term Safety Study of Amifampridine Phosphate in MuSK-MG (Muscle Specific Tyrosine Kinase Myasthenia Gravis)","status":"TERMINATED","sponsor":"Catalyst Pharmaceuticals, Inc.","startDate":"2018-06-11","conditions":"Myasthenia Gravis, MuSK, AChR Myasthenia Gravis","enrollment":63},{"nctId":"NCT03062631","phase":"","title":"Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia","status":"NO_LONGER_AVAILABLE","sponsor":"Ricardo Maselli","startDate":"","conditions":"Congenital Myasthenic Syndrome","enrollment":""},{"nctId":"NCT00872950","phase":"","title":"3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)","status":"APPROVED_FOR_MARKETING","sponsor":"Lahey Clinic","startDate":"","conditions":"Lambert-Eaton Myasthenic Syndrome, Congenital Myasthenic Syndrome","enrollment":""},{"nctId":"NCT01825395","phase":"","title":"Use of 3,4-Diaminopyridine in the Treatment of Lambert-Eaton Syndrome","status":"APPROVED_FOR_MARKETING","sponsor":"University of Colorado, Denver","startDate":"","conditions":"Lambert Eaton Myasthenic Syndrome","enrollment":""},{"nctId":"NCT03781479","phase":"PHASE2","title":"Controlled Trial to Evaluate Amifampridine Phosphate in Spinal Muscular Atrophy Type 3 Patients","status":"COMPLETED","sponsor":"Catalyst Pharmaceuticals, Inc.","startDate":"2019-01-21","conditions":"Muscular Atrophy, Spinal","enrollment":13},{"nctId":"NCT02562066","phase":"PHASE3","title":"Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes","status":"COMPLETED","sponsor":"Catalyst Pharmaceuticals, Inc.","startDate":"2016-01","conditions":"Myasthenic Syndromes, Congenital","enrollment":20},{"nctId":"NCT02012933","phase":"","title":"3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome (LEMS) and Congenital Myasthenia (CM)","status":"NO_LONGER_AVAILABLE","sponsor":"Oregon Health and Science University","startDate":"","conditions":"Lambert-Eaton Myasthenic Syndrome (LEMS), Congenital Myasthenia (CM)","enrollment":""},{"nctId":"NCT00704925","phase":"","title":"Treatment of Lambert-Eaton Syndrome With 3,4 DAP","status":"NO_LONGER_AVAILABLE","sponsor":"David P. Richman, MD","startDate":"","conditions":"Lambert Eaton Myasthenic Syndrome","enrollment":""},{"nctId":"NCT00994916","phase":"","title":"Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine","status":"NO_LONGER_AVAILABLE","sponsor":"David Lacomis, MD","startDate":"","conditions":"Lambert-Eaton Myasthenic Syndrome","enrollment":""},{"nctId":"NCT02090725","phase":"PHASE2","title":"Controlled Trial of 3,4-Diaminopyridine (3-4DAP) in Lambert-Eaton Myasthenic Syndrome (LEMS)","status":"TERMINATED","sponsor":"Jeffrey A. Cohen, MD","startDate":"2004-02","conditions":"Muscle Weakness","enrollment":4},{"nctId":"NCT01377922","phase":"PHASE3","title":"A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)","status":"COMPLETED","sponsor":"Catalyst Pharmaceuticals, Inc.","startDate":"2011-06","conditions":"Lambert Eaton Myasthenic Syndrome","enrollment":38},{"nctId":"NCT01511978","phase":"PHASE2","title":"Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome","status":"COMPLETED","sponsor":"Jacobus Pharmaceutical","startDate":"2012-01","conditions":"Lambert-Eaton Myasthenic Syndrome, Eaton-Lambert Myasthenic Syndrome","enrollment":32},{"nctId":"NCT01373333","phase":"","title":"Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome","status":"NO_LONGER_AVAILABLE","sponsor":"The Cleveland Clinic","startDate":"1997-09","conditions":"Lambert-Eaton Myasthenic Syndrome","enrollment":""},{"nctId":"NCT00004832","phase":"NA","title":"Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome","status":"COMPLETED","sponsor":"FDA Office of Orphan Products Development","startDate":"1994-08","conditions":"Lambert-Eaton Myasthenic Syndrome","enrollment":26},{"nctId":"NCT01378546","phase":"","title":"Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP","status":"NO_LONGER_AVAILABLE","sponsor":"Louis H. Weimer, MD","startDate":"2005-05","conditions":"Lambert Eaton Myasthenic Syndrome (LEMS)","enrollment":""},{"nctId":"NCT00190268","phase":"PHASE3","title":"Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2005-02","conditions":"Multiple Sclerosis","enrollment":126},{"nctId":"NCT00342381","phase":"PHASE2","title":"Fatigue in Multiple Sclerosis: Evaluated With 3 MRI and Transcranial Magnetic Stimulation","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2006-06","conditions":"Multiple Sclerosis, Fatigue","enrollment":120},{"nctId":"NCT00004939","phase":"PHASE3","title":"Phase III Randomized, Double-Blind, Placebo-Controlled Study of 3,4-Diaminopyridine for Demyelinating Polyneuropathy","status":"COMPLETED","sponsor":"National Center for Research Resources (NCRR)","startDate":"1996-08","conditions":"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","enrollment":34}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":578,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":",4-diaminopyridine","genericName":",4-diaminopyridine","companyName":"National Center for Research Resources (NCRR)","companyId":"national-center-for-research-resources-ncrr","modality":"Small molecule","firstApprovalDate":"","aiSummary":"3,4-diaminopyridine blocks potassium channels on nerve terminals, prolonging action potentials and increasing acetylcholine release at the neuromuscular junction. Used for Lambert-Eaton myasthenic syndrome (LEMS), Myasthenia gravis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}